BioSpace News Archive

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the United States Patent Office (USPTO) issued U.S. Patent No. 10,946,036 with an expiry of June 2037

Merger accompanied by £3.8million ($5.3m USD) investment across shareholders, which will be used to fund recruitment and growth of the business

Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD

Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower doses

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has acquired BFS Molecular S.R.L., a software company focused on NGS-based patient testing solutions.

Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced today that it has entered into a License Agreement with Torii Pharmaceutical Co., Ltd.

VBL Therapeutics (Nasdaq: VBLT) will release its fourth quarter and full year results for the period ended December 31, 2020 on Thursday, March 25, 2021 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer, will host a conference call at 8:30am ET the same day to discuss the results and provide a corporate update.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (“A.I.”) platform to transform oncology drug discovery and development today announced that it has filed seven patent applications globally on a novel DNA-damaging agent with anticancer properties.

Renowned Biotech Industry Innovator is Senior Partner at Flagship Pioneering, a member of Moderna Therapeutics’ Development Committee and former Chief Medical Officer of Merck

- Dr. David Huang, leader in anti-infective drug development, to serve as SVP, Chief Medical Officer - Dr. Nick Nystrom, global leader in life sciences AI, to serve as SVP, Computing & Data - Nicholas Pachuda, seasoned expert in business strategy, to serve as SVP, Portfolio Strategy & Development